Orbis Microbubble Generator
Commercial- Indications
- Cardiac imaging
Company intelligence / Profile preview
Agitated Solutions has received FDA IND clearance to initiate a Phase 3 multi-center trial of its novel right heart ultrasound contrast agent, ASI‑02, designed to improve the consistency and quality of cardiac bubble studies. The company’s Orbis Microbubble Generator is licensed by Health Canada and is being used clinically at key Canadian centers. Early results highlight improved workflow efficiency, single operator use, more consistent microbubbles, and enhanced diagnostic accuracy compared to manual methods. No commercial availability outside Canada as of mid‑2025
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Agitated Solutions.